Lipase inhibition: a novel concept in the treatment of obesity

摘要: Orlistat (Ro 18-0647) is an inhibitor of gastric, carboxylester and pancreatic lipase specifically reduces the absorption dietary fat due to inhibition triglyceride hydrolysis. can be used for treatment obesity. Of 52 healthy obese patients entering a four-week single-blind run-in period with diet (500 kcal-reduced, containing 30% calories in form fat) placebo three times day, 44 showed compliance by reducing their body weight 0.5-4 kg from screening. These were randomized 12-week double-blind, parallel group, placebo-controlled 50 mg or day. Complete data available 39 patients, 20 on (3 men, 17 women; mean 85.5 +/- 12.1 kg; mass index 30.6 3.7 kg/m2) 19 16 81.9 7.9 30.0 2.6 kg/m2. Total loss after randomization was 4.3 3.4 group 2.1 2.8 (P = 0.025, analysis variance repeated measurements; 95% confidence interval difference 0.2-4.2 kg). Gastrointestinal side effects seen but most symptoms mild transient. One patient dropped out because faecal incontinence. No effect vitamin A levels, E levels became lower < 0.05, paired t test).(ABSTRACT TRUNCATED AT 250 WORDS)